8-K: Acrivon Therapeutics Updates on Clinical Pipeline and AP3 Platform

Acrivon Therapeutics provided a corporate presentation detailing strong preclinical synergy for its lead candidates with immune checkpoint inhibitors and positive clinical data for ACR-368 in endometrial cancer.

Summary

• Updated corporate presentation highlights continued strong synergy between clinical candidates ACR-368 and ACR-2316 with immune checkpoint inhibitors in syngeneic mouse models.
• Observed complete tumor regression and immune memory over almost one year in preclinical models, supporting combination with anti-PD(L)1 agents in front-line settings.
• The pipeline overview for the ACR-368-201 trial now includes the all-comer ACR-368 + ULDG ARM 3.
• The Generative Phosphoproteomics AP3 platform capabilities were highlighted for novel drug design and development, generating actionable, differentiated pathway-based insights.
• ACR-368 demonstrated a 35% confirmed Objective Response Rate (cORR) in OncoSignature-positive endometrial cancer patients (N=20), which is 3x higher than the Best Overall Response (BOR) in their last prior line of therapy.
• In relapsed patients, ACR-368 showed a 50% ORR, median Duration of Response (mDoR) >10 months (not reached), and 100% Disease Control Rate (DCR).
• ACR-2316 Phase 1 trial has cleared Dose Levels 1, 2, and 3 without safety concerns, with initial clinical activity including a confirmed partial response in an endometrial cancer patient.
• Cash and investments stood at $147.6 million as of June 30, 2025, providing a projected runway into Q2 2027.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical and preclinical data for both lead candidates, ACR-368 and ACR-2316, particularly in challenging cancer indications. The accelerated development of ACR-2316 and the robust performance of the AP3 platform are significant positives. While financial runway is noted, it's within expectations for a biotech at this stage, and the overall tone and reported results are highly encouraging for future prospects.

Positives

• Strong preclinical synergy observed between ACR-368 and ACR-2316 with immune checkpoint inhibitors, leading to complete tumor regression and immune memory in syngeneic mouse models.
• ACR-368 achieved a 35% confirmed Objective Response Rate (cORR) in OncoSignature-positive endometrial cancer patients (N=20), significantly higher than prior therapies.
• ACR-368 demonstrated durable responses in relapsed endometrial cancer patients with a 50% ORR, median Duration of Response (mDoR) >10 months (not reached), and 100% Disease Control Rate (DCR).
• ACR-2316 Phase 1 trial has successfully cleared Dose Levels 1, 2, and 3 without safety concerns or dose-limiting toxicities.
• Initial clinical activity, including a confirmed partial response, has been observed for ACR-2316 in an endometrial cancer patient during dose escalation.
• The company achieved IND clearance for ACR-2316 and dosed the first patient two quarters ahead of schedule, demonstrating efficient development.
• The AP3 Generative Phosphoproteomics platform is highlighted as a robust tool for drug design, target identification, and biomarker discovery.
• Cash and investments of $147.6 million as of June 30, 2025, provide a projected operational runway into Q2 2027.

Negatives

• The safety data for ACR-368 shows Grade 3/4 adverse events including Thrombocytopenia (15% in OncoSignature-positive, 35% in OncoSignature-negative), Anemia (27% in OncoSignature-positive, 45% in OncoSignature-negative), and Neutropenia (27% in OncoSignature-positive, 24% in OncoSignature-negative).

Risks

• The outcome of forward-looking statements is subject to risks and uncertainties, including factors described in SEC filings.
• New risks and uncertainties may emerge, and it is not possible to predict all potential impacts on forward-looking statements.
• Actual results, events, or circumstances could differ materially from those described in forward-looking statements.
• Clinical trials inherently carry risks of not achieving desired efficacy or safety profiles, despite promising early data.
• The projected cash runway into Q2 2027 assumes no additional financing, indicating potential future capital needs.

Future Outlook

Acrivon Therapeutics anticipates initial clinical data for ACR-368 monotherapy and ACR-2316 Phase 1 trial in the second half of 2025. An update on the ACR-368 Phase 2 registrational intent trial and confirmatory trial design is also expected in the second half of 2025. The company plans to initiate the ACR-368 biomarker unselected (all-comer) arm in 2nd line endometrial cancer in the ongoing Phase 2 trial. Development candidate nomination for a novel cell cycle program and target/compound validation for a new autoimmune/inflammatory program are also expected in 2025. The company projects its current cash and investments to provide a runway into Q2 2027, assuming no additional financing.

Management Comments

• Our forward-looking statements are based primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and results of operations.
• The outcome of the events described in the forward-looking statements is subject to risks and uncertainties, including the factors described in our filings with the U.S. Securities and Exchange Commission.
• New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this presentation.
• The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.
• We undertake no obligation to update any forward-looking statements or to reflect new information or the occurrence of unanticipated events, except as required by law.

Industry Context

The updates position Acrivon Therapeutics as a key player in precision oncology, leveraging its proprietary AP3 platform to identify patient responders and develop targeted therapies. The focus on combination therapies with immune checkpoint inhibitors (anti-PD(L)1) aligns with a major industry trend to enhance efficacy and overcome resistance in various cancers, particularly in the evolving landscape of endometrial cancer treatment where combination regimens are becoming standard. The development of WEE1/PKMYT1 inhibitors also addresses a critical cell cycle checkpoint, a common strategy in DNA Damage Response (DDR) inhibition, an active area of research in oncology. The company's ability to accelerate drug development (e.g., ACR-2316 from lead to Phase 1 in 15 months) using its platform suggests a competitive advantage in a fast-paced industry.

Comparison to Industry Standards

• The 35% cORR for ACR-368 in heavily pre-treated endometrial cancer patients (relapsed after prior platinum-based chemotherapy and anti-PD-(L)1 therapy) compares favorably to historical response rates of 10-12% for chemotherapy in the second-line setting for this patient population.
• The observed 50% ORR and mDoR >10 months in relapsed patients for ACR-368 are strong indicators of efficacy, especially given the challenging nature of this patient population.
• The rapid progression of ACR-2316 from initial lead to first patient dosed in Phase 1 within 15 months, enabled by the AP3 platform, demonstrates a significantly streamlined development timeline compared to typical industry averages for novel drug candidates.
• The preclinical synergy of ACR-368 and ACR-2316 with anti-PD-(L)1 agents, leading to complete tumor regression and immune memory, aligns with and potentially surpasses results seen with other DDR inhibitor combinations in preclinical settings, such as those reported by companies like AstraZeneca (with PARP inhibitors) or Merck (with CHK1 inhibitors).
• The safety profile of ACR-368, characterized by 'limited, transient, reversible, mechanism-based hematological AEs' and a 'notable absence of GI toxicities, long-lasting myelosuppression or more severe non-hematological AEs commonly seen with ADCs and chemotherapy,' suggests a potentially more favorable tolerability profile compared to many standard-of-care chemotherapies or antibody-drug conjugates (ADCs) like T-Dxd (Trastuzumab Deruxtecan) which can have more severe non-hematological toxicities.

Stakeholder Impact

• Shareholders: Positive clinical and preclinical data, along with accelerated development timelines, could increase investor confidence and potentially lead to share price appreciation. The projected cash runway provides clarity on near-term financial stability.
• Patients: Promising efficacy data for ACR-368 and initial activity for ACR-2316 offer hope for new treatment options, especially for those with heavily pre-treated or aggressive cancers.
• Healthcare Providers: The development of precision medicine tools like OncoSignature and the AP3 platform could provide clinicians with better tools for patient stratification and treatment selection.
• Employees: Positive pipeline progress and financial stability can boost morale and job security.

Next Steps

• Initial clinical data for ACR-2316 Phase 1 trial in 2H 2025.
• Update on ACR-368 Phase 2 registrational intent trial and confirmatory trial design in 2H 2025.
• Initiation of ACR-368 biomarker unselected (all-comer) arm in 2nd line endometrial cancer in the ongoing Phase 2 trial.
• Development candidate nomination for novel cell cycle program in 2025.
• Target/compound validation and indication finding for new program in autoimmune/inflammatory diseases leveraging AP3 in 2025.
• Continued enrollment of patients in DL4 for ACR-2316 Phase 1 study.
• Further development of ACR-368 in other high unmet need tumor types like MDS/MPN and SCC.
• Exploration of ACR-368 combination opportunities with anti-PD-(L)1 inhibitors, ADCs, ACR-2316, CDK4/6 inhibitors, and K-Ras inhibitors.

Key Dates

Recommendation

The filing provides highly encouraging clinical data for ACR-368, demonstrating superior efficacy (35% cORR, 3x higher than prior lines) and durability in a challenging, heavily pre-treated endometrial cancer population. The initial clinical activity of ACR-2316 in its early-stage trial, coupled with its accelerated development timeline, further de-risks the pipeline. The proprietary AP3 platform appears to be a significant competitive advantage, enabling both drug discovery and patient stratification. With a cash runway into Q2 2027 and multiple upcoming milestones in 2H 2025, the company is well-positioned for continued progress. The strong preclinical synergy with immune checkpoint inhibitors also opens up substantial market opportunities. These factors collectively suggest a strong growth trajectory and significant upside potential for the stock.

Keywords

Acrivon Therapeutics, ACRV, SEC Filing, 8-K, Corporate Presentation, Precision Medicine, AP3 Platform, ACR-368, CHK1/CHK2 Inhibitor, ACR-2316, WEE1/PKMYT1 Inhibitor, OncoSignature, Endometrial Cancer, Oncology, Clinical Trials, Drug Development, Immune Checkpoint Inhibitors, Biotechnology, Financial Update